Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-07-17
2007-07-17
Ungar, Susan (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387700, C530S388100
Reexamination Certificate
active
09250056
ABSTRACT:
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
REFERENCES:
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5696237 (1997-12-01), Fitzgerald et al.
patent: 5733782 (1998-03-01), Dorai et al.
patent: 5885793 (1999-03-01), Griffiths et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: WO 91/0996 (1991-07-01), None
patent: 92/22653 (1992-12-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 94/13804 (1994-06-01), None
patent: 9426787 (1994-11-01), None
patent: WO 94/26787 (1994-11-01), None
patent: WO 96/21007 (1996-07-01), None
patent: WO 97/00271 (1997-01-01), None
patent: WO 97/10330 (1997-03-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 97/45544 (1997-12-01), None
patent: WO 98/05344 (1998-02-01), None
patent: WO 99/10014 (1999-03-01), None
Ishida et al., Jpn. J. Cancer Res. 85:172-178, 1994.
Knight BioTechnology vol. 7 No. 1, 1989.
Rudikoff et al., Proc Natl. Acad Sci. USA 79 p. 1979, 1982.
Panka et al., Proc. Natl. Acad. Sci. USA 85:3080-84, 1988.
Amit et al., Science 233:747-753, 1986.
George et al., Macromolecular Sequenceing and Synthesis, pp. 127-149, 1988.
Barton et al., Protein Structural Prediction, A practical Approach, pp. 31-63, 1996.
Paul, fundamental Immunology 242, 1993.
Maier et al., Cancer Res. 51:5361-69, 1991.
Greenspan et al., Nature Biotechnology vol. 17, pp. 936-937, 1999.
Bird et al., Science 242:423-4426, 1988.
Mandler et al J of the National Cancer inst 92:1573-1581, 2000.
Park et al., J of Controlled release 74:95-113, 2001.
Mendelsohn Journal of the National Cancer Inst. 92:1549-1551, 2000.
Chaudhary et al PNAS 87:1066-70, 1990.
Xu et al Int J Cancer 53:401-408, 1993.
Shawver et al Cancer Res 54:1367-1373, 1994.
Colman Research in Immunology 145:33-36, 1994.
Altenschmidt et al., “Targeted Therapy of Schwannoma Cells in Immunocompetent Rats with an erbB2-Specific Antibody-Toxin”, International Journal of Cancer, Sep. 26, 1997, vol. 73, No. 1, pp. 117-124.
Barry, et al., “Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries”, Nature Medicine, Mar. 1996, vol. 2, No. 3, pp. 299-305.
Fominaya, et al., “Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein”, Journal of Biological Chemistry, May 3, 1996, vol. 271, No. 18, pp. 10560-10568.
Hart, et al., “Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide”, Journal of Biological Chemistry, Apr. 29, 1994, vol. 269, No. 17, pp. 12468-12474.
Okayama, et al., “Bacteriophage Lambda Vector for Transducing a cDNA Clone Library into Mammalian Cells”, Molecular and Cellular Biology, May 1985, vol. 5, No. 5, pp. 1136-1142.
Larocca et al., “Targeting Bacteriophage to Mammalian Cell Surface Receptore for Gene Delivery”, Human Gene Therapy, Nov. 1, 1998, vol. 9, pp. 2393-2399.
Kirpotin et al., “Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells inVitro”, Biochemistry, Jan. 7, 1997, vol. 36, No. 1, pp. 66-75.
Schier, et al., “in vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library”, Immunotechnology, 1995, vol. 1, pp. 73-81.
Schier, et al., “Identification of functional and structural amino-acid residues by parsimonious mutagenesis”, Gene, Mar. 9, 1996, vol. 169, No. 2, pp. 147-155.
Schier, et al., “Efficientin vitroaffinity maturation of phage antibodies using BIAcore guided selections”, Hum. Antibod. Hybridomas, 1996, vol. 3, No. 7, pp. 97-105.
Schier, et al., “Isolation of High-affinity monomeric Human Anti-c-erB-2 Single chain Fv Using Affinity-driven Selection”, Journal of Molecular Biology, Jan. 12, 1996, vol. 255, No. 1, pp. 28-43.
Schier , et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site”, Journal of Molecular Biology, Jan. 12, 1996, vol. 263, No. 4, pp. 551-567.
Slamon, et al., Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer, American Association for the Advancement of Science, May 12, 1989, vol. 244, No. 4905, pp. 707-712.
Yokoyama-Kobayashi, et al., “Recombinant fl Phage Particles Can Transfect Monkey COS-7 Cells by DEAE Dextran Method”, Biochemical and Biophysical Research Communication, Apr. 30, 1993, vol. 192, No. 2, pp. 935-939.
Borrebaeck Carl A.K., “Strategy for the production of human monoclonal antibodies using in vitro activated B cells”, Journal of Immunological Methods, vol. 123, 1989, pp. 157-165.
Disis, et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients with Breast Cancer”, Cancer Research, vol. 54, Jan. 1, 1994, pp. 16-20.
Huston, et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, Proceedings of the National Academy of Sciences, vol. 85, Aug. 1988, pp. 5879-5883.
Vallera Daniel A., “Immunotoxins: Will Their Clinical Promise be Fulfilled”, Blood: The Journal of The American Society of Hematology, vol. 83, No. 2, Jan. 15, 1994, pp. 309-317.
Soderlind, et al., “Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors andin vitroMaturation Systems”, Immunological Reviews, 1992, No. 130, pp. 109-124.
Trail, et al., “Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates”, Science, Jul. 9, 1993, vol. 261, pp. 212-215.
Weiner, et al., Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin a Chain Immunoconjugate, Cancer Research, vol. 49, Jul. 15, 1989, pp. 4062-4067.
Riethmuller, et al., “Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers”, Current Opion in Immunology, 1992, vol. 4, pp. 647-655.
Brinkmann, et al., “A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form ofPseudomonasexotoxin”, Procedings of the National Academy of Sciences, Jan. 1993, vol. 90, pp. 547-551.
Colcher, et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies”, Cancer Research, Aug. 15, 1988, vol. 48, pp. 4597-4603.
Gallinger, et al., “Comparative Dual Label Study of First and Second Generation Antiumor-associated Glycoprotein-72 Monoclonal Antibodies in Colorectal Cancer Patients”, Cancer Research, Jan. 15, 1993, vol. 53, pp. 273-278.
Adams, et al., highly Specificin VivoTumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single Chain Fv.
Hoogenboom, et al., “Building Antibodies from their Genes” , Immunological Reviews, 1992, No. 130, pp. 41-68.
Marks, et al., “By-passing Immunization Human: Human antibodies from V-gene Libraries Displayed on Phage”, Journal of Mol. Biology, 1991, vol. 222, pp. 581-597.
Marks, et al., “By-passing Immunization Human: Building High Affinity Human Antibodies by Chain Shuffling”, Bio/Technology, Jul. 1992, vol. 10., pp. 779-783.
Hawkins, et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”, Journal of Mol. Biology, 1992, vol. 226, pp. 889-896.
Reichmann, et al., “Phage Display and Selection of a Site-Directed Randomized Single-Chain Antibody Fv Fragment for Its Affinity Improvement”, Biochemistry, 1993,
Marks James D.
Poul Marie Alix
Quine Intellectual Property Law Group P.C.
The Regents of the University of California
Ungar Susan
LandOfFree
Internalizing ERB2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Internalizing ERB2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internalizing ERB2 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731750